BioSpace News Archive

Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share.

Blue Cross Blue Shield of Massachusetts’ Alternative Quality Contract slowed the rate of medical spending growth by up to 12% while improving patient care over the course of eight years, Harvard Medical School researchers report in a landmark study published in the New England Journal of Medicine.

QuickFire Challenge seeks to identify and accelerate game-changing, early-stage health tech innovations from around the world.

Bausch Health Companies Inc. and Progenics Pharmaceuticals, announced that the U.S. District Court of New Jersey upheld the validity and determined Actavis’ infringement of a patent protecting RELISTOR® tablets, expiring March 2031.

Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, announced the appointment of Douglas S. Ingram and Deep Nishar to its board of directors.

Plan will accelerate efforts to prevent, diagnose and treat sexually transmitted and blood-borne infections, and address barriers to care

GenScript Biotech Corp., one of the leading Biologics contract development and manufacturing organizations in China, announced that its Biologics research and development and production center was formally put into operation on July 11, 2019.

Phreesia, Inc., a leading patient intake management platform, announced the pricing of its initial public offering of 9,288,194 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts, consisting of 7,812,500 shares to be issued and sold by Phreesia and 1,475,694 shares to be sold by certain of Phreesia’s existing stockholders.

Complimentary Exhibit Hall & Keynote Passes Available for Experts, Advisors, Students and “Citizen Scientists”

The global rapid self-healing gel market is expected to post a CAGR of over 7% during the period 2019-2023, according to the latest market research report by Technavio.